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To the Editor:
This timely letter from Lo´pez-Bigas et al. dramatically
illustrates the complexity of hearing loss associated with
mitochondrial mutations. In a relatively large sample of
209 families with deafness, they identified 42 families
with the A1555G mutation in the 12S rRNA gene. They
demonstrate a 50% penetrance for the phenotype of
deafness in all individuals who were positive for the
mutation, with a wide range in the age at onset of deaf-
ness. A history of aminoglycoside exposure was noted
in only 20% of their deaf subjects who were also positive
for the mutation. Analysis of 42 unrelated patients with
the A1555G mutation for additional mitochondrial var-
iants, such as the G7444A substitution in the tRNA ser
(UCN) gene, or for mutations in the nuclear Connexin
26 gene were negative. Although their results clearly ex-
clude mutations at these two loci as epistatic modifiers
of the A1555G phenotype in Spain, it remains to be
determined whether the G7444A mutation(s) account
for variation in other populations, such as Mongolia,
where a substantial proportion of patients with the
A1555G substitution appear to carry the double mu-
tation. Preliminary work in individuals who test positive
for the A1555G mutation in the Chinese population has
failed to reveal a mutation in the tRNA ser (UCN) gene.
Another phenotypic difference in students with the
A1555G/G7444A double mutation is the presence of
hearing loss by age 2 years in most of our probands,
compared with the later onset of deafness in the Spanish
individuals who have no exposure to aminoglycosides.
With widespread use of aminoglycoside antibiotics in
certain developing nations, a negative history of expo-
sure may not always be reliable. We agree that there is
a need to evaluate the possible role of other compounds
as well as to consider the implications of oral absorption
of aminoglycosides (Kunin et al. 1960; Breen et al. 1972)
in carriers of the A1555G mutation who have height-
ened sensitivity to ototoxicity. In a population such as
Spain, where the A1555G mutation is such a frequent
cause for deafness, phenotypic comparisons within even
a few sets of twins could provide critical evidence of the
extent to which inherited differences in nuclear or cy-
toplasmic modifier genes do, in fact, contribute to var-
iation in the A1555G phenotype.
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